143782-21-2

Basic information

• Product Name: 2-(5,5-dimethyl-3-(4-cyano-3-(trifluoromethyl)phenyl)-2,4-dioxoimidazolin-1-yl)acetic acid
• Synonyms: 2-(5,5-dimethyl-3-(4-cyano-3-(trifluoromethyl)phenyl)-2,4-dioxoimidazolin-1-yl)acetic acid
• CAS NO: 143782-21-2
• Molecular Weight: 355.273
• Mol File: 143782-21-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(5,5-dimethyl-3-(4-cyano-3-(trifluoromethyl)phenyl)-2,4-dioxoimidazolin-1-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5,5-dimethyl-3-(4-cyano-3-(trifluoromethyl)phenyl)-2,4-dioxoimidazolin-1-yl)acetic acid(143782-21-2)
• EPA Substance Registry System: 2-(5,5-dimethyl-3-(4-cyano-3-(trifluoromethyl)phenyl)-2,4-dioxoimidazolin-1-yl)acetic acid(143782-21-2)

Safety Data

• Hazardous Substances Data: 143782-21-2(Hazardous Substances Data)

Upstream product

• 79-08-3 bromoacetic acid 
• 143782-20-1 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 194853-86-6 4-fluoro-2-(trifluoromethyl)benzonitrile 
• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 143782-22-3 2-(5,5-dimethyl-3-(4-cyano-3-(trifluoromethyl)phenyl)-2,4-dioxoimidazolin-1-yl) ethyl acetate 

Relevant articles and documents

Novel androgen receptor degradation agent, preparation method and medical application

The invention discloses a novel androgen receptor degradation agent with a structure as shown in a general formula I or a general formula II, a preparation method and medical application. Pharmacological experiments prove that the compound has good anti-prostatic cancer activity, and is especially suitable for preparing drugs for treating androgen receptor related diseases such as prostatic cancer and the like.

Phenylimidazolidines having antiandrogenic activity

A compound of the formula STR1 wherein R1 is --CN, --NO2 or halogen, R2 is --CF3 or halogen, --A--B-- is of STR2 X is --O-- or --S--, R3 is hydrogen, alkyl, alkenyl or alkynyl of up to 12 carbon atoms, aryl and aralkyl of up to 12 carbon atoms, all optionally substituted by --OH, halogen, --SH, --CN, acyl and acyloxy of up to 7 carbon atoms, --aryl, --O--aryl, --O--aralkyl --S-- aryl of up to 12 carbon atoms the aryl and aralkyl being optionally substituted by halogen, --CF3, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl or alkynyloxy with the sulfur being optionally oxidized to sulfone or sulfoxide, free, esterified, amidified or salified carboxy, --NH2, mono and dialkylamino and heterocyclic of 3 to 6 ring members and containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, the alkyl, alkenyl and alkynyl being optionally interrupted by at least one oxygen, nitrogen or sulfur optionally oxidized to sulfoxide or sulfone, trialkylsilyl with the alkyl having 1 to 6 carbon atoms and acyl and acyloxy of an organic carboxylic acid of 1 to 7 carbon atoms and Y is --O--, --S-- or --NH--, except the compounds wherein --A-B-- is STR3 X is oxygen, R3 is hydrogen and Y is oxygen or --NH--, R2 is --CF3 or halogen and R1 is --NO2 or halogen and their non-toxic, pharmaceutically acceptable acid addition salts.